KIT and cancer: The importance of progression-free survival has been shown across a variety of cancer types and is associated with a clinically relevant deterioration in quality of life.36 For these reasons, the cost-effectiveness of withholding futile therapy for patients with KIT exon 9 variation is not surprising.